BOSTON SCIENTIFIC CORP (BSX): what the price assumes

In the published model solve dated 2026-Q2, anchored at $46.85, BOSTON SCIENTIFIC CORP (BSX) is priced for +4.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-07.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/BSX

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 9: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.7% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• The Cardiovascular business, roughly twice the size of MedSurg at $13.3 billion of revenue, grew net sales 8.3% in the June 2026 quarter while MedSurg grew 5.9%, and the whole company grew 7.5% to $5.442 billion.
• Guidance points sharply lower from here: third-quarter net sales growth is guided to roughly 3 to 5 percent, against 7.0 percent organic growth just delivered, and on July 21, 2026 the board approved a restructuring plan carrying pre-tax charges of $700 million to $800 million.
• The balance sheet did most of the work this quarter, funding a completed $2 billion accelerated share repurchase of roughly 40 million shares and a $1.5 billion investment in MiRus for about a third of that company, which took cash and equivalents down to 539 million dollars from 1,965 million at the year end.

Bull Case

Watch where a company sends its money and you learn what management actually believes. In the June 2026 quarter Boston Scientific did two things at once: it finished a $2 billion accelerated share repurchase, retiring roughly 40 million shares, and it put $1.5 billion into MiRus for an approximately 34% equity stake plus an exclusive option to acquire that company's transcatheter aortic valve replacement business. Buying back stock says the shares look cheap to the people who see the forecast. Buying an option on a valve platform says they are not finished expanding the addressable list of procedures. Doing both in three months, and taking cash and equivalents down to 539 million dollars from 1,965 million at the start of the year to do it, is not the behaviour of a management team hedging.

The operating results underneath give the confidence some grounding. Net sales reached $5.442 billion, up 7.5 percent reported and 7.0 percent organic, above the top of the company's own 5 to 7 percent organic guidance range. Operating income was $1,178 million against $819 million a year earlier, and reported earnings came to $0.61 a share against $0.53. Both reportable segments grew: Cardiovascular 7.8 percent organic and MedSurg 5.4 percent. Geographic breadth backs it up, with Asia-Pacific up 11.2 percent and Latin America and Canada up 16.2 percent on an operational basis.

The competitive position rests on being the category leader in narrow, high-value procedure niches rather than on scale. The 10-K frames the strategy around a set of imperatives that include Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities, and the pipeline shows what that looks like in practice. During the quarter the AVANT GUARD study of FARAPULSE pulsed field ablation in persistent atrial fibrillation met all safety and effectiveness endpoints and demonstrated statistical superiority over anti-arrhythmic drugs in patients who had not been treated before, and the company began enrolment in the pivotal FARADIGM trial of a new mapping and ablation catheter. Superiority against drug therapy in treatment-naive patients is the kind of finding that moves a procedure earlier in the treatment pathway, which expands the eligible population rather than merely taking share within it.

Margins already sit where they need to be rather than where they need to get to. The trailing operating margin runs around 18.4 percent, which places the company between MDT at 17.8 percent and SYK at 21.4 percent on their most recent trailing years, and above ABT at 17.1 percent. Growth is the differentiator: the June quarter's 7.5 percent reported expansion compares with trailing-year revenue growth of 8.4 percent for MDT, 8.5 percent for SYK and 6.6 percent for ABT. Boston Scientific is growing at roughly the pace of the best of its large peers while earning a comparable margin, which is a more defensible combination than either one alone.

Then there is the cost programme, which is a lever rather than a repair. The restructuring plan approved on July 21, 2026 is expected to reduce gross annual pre-tax expenses by approximately $500 million once the benefits land, against total pre-tax charges of $700 million to $800 million spread through 2029, with a substantial portion of the savings earmarked for reinvestment. Interest is a small claim on all of this: operating income covers the interest bill about 10.6 times over, with interest expense of $96 million in the quarter against operating income of $1,178 million. A business generating that much coverage has room to spend against a multi-year plan without the balance sheet dictating the pace.

Bear Case

Today's price leans on one specific assumption, and the company has just told the market that assumption is about to be tested. Paying about 21 times operating income embeds company-wide operating profit growth of roughly 8.9 percent a year over the next five years. Third-quarter guidance, issued July 29, 2026, calls for net sales growth of approximately 3 to 5 percent, against the 7.0 percent organic rate just delivered. Even allowing for comparison effects, a step down of that size in the very next quarter is a poor start on a five-year requirement, and profit growth cannot outrun sales growth indefinitely without margin expansion doing the work.

The margin lever is where the fragility concentrates. On July 21, 2026 the board approved a global restructuring plan expected to cost $700 million to $800 million pre-tax, of which $600 million to $700 million eventually leaves as cash, in exchange for roughly $500 million of annual gross expense reduction by the time it completes at the end of 2029. The company also says a substantial portion of those savings will be reinvested. Read plainly, that is management spending real money over four years to hold the margin roughly where it already is while funding growth. That is a perfectly sensible plan. It is not a plan that produces the margin expansion an accelerating profit line would need.

The pricing environment explains why. The 10-K states that We continue to experience pressures across many of our businesses due to competitive activity, increased market power of our customers as the health care industry consolidates, national and regional government tenders, economic pressures experienced by our customers, and adds that We also encounter competition from the entry of low-cost manufacturers, which may lead to increased pricing pressure. In certain countries, and particularly in China, we face competition from domestic medical device companies that may benefit from their status as local suppliers. Medical devices are sold to consolidated buyers through tenders. That is a structure in which unit growth is available and price growth generally is not.

The reported profit also flatters itself in a way worth naming. Over the first half of 2026 the company recorded an income tax benefit of $21 million rather than an expense, on pre-tax income of $2,222 million. Net income of $2,243 million therefore exceeded pre-tax income. Tax outcomes like that arise from discrete items and do not repeat, so any read of profitability that starts below the operating line for this period is reading something that will not be there next year.

Where the methods disagree is instructive rather than alarming. The price sits about 57 percent above where the asset-value methods land and about 85 percent above the earnings-power methods, which capitalize what the business earns today with no growth credited at all. Peer multiples and the cash-flow methods, which do credit growth, both land above the current quote. Read together, that is a price defended entirely by growth continuing, with nothing underneath it from what the company owns or currently earns. The reference points supporting the growth assumption are also thinner than they look: the pace is within what the company has recently delivered, and the multiple sits in the lower half of its peer group, but those two observations are most of the evidence base here.

Finally, the balance sheet has less slack than it did six months ago. Cash and equivalents fell to $539 million on June 30, 2026 from $1,965 million at the year end, spent on the repurchase and the MiRus stake, while debt obligations totalled $12,624 million between current and long-term. The MiRus holding sits inside other investments, which rose to $2,245 million from $681 million, and it is a genuine floor under part of the downside. It is also an option on an investigational device, which is a different asset from a cash balance when a difficult quarter arrives.

Valuation

Start with what today's price requires rather than with what it costs. Paying roughly 21 times operating income for Boston Scientific embeds company-wide operating profit growth of about 8.9 percent a year for five years, computed against a 7.9 percent cost of capital. That figure is worth holding loosely: shift the cost of capital by a single percentage point and the implied growth requirement moves by roughly 7.5 points, which tells you the answer is far more sensitive to the discount assumption than to anything in the operating forecast.

Measured against the references available, the requirement reads as reasonable rather than heroic. The pace is inside what the company has recently delivered, and the multiple sits in the lower half of its peer group rather than at the top. Those two observations carry most of the weight here, which makes the conclusion narrower than a comfortable verdict. Trailing operating margin runs around 18.4 percent, so this is a requirement about maintaining growth on an already-healthy base, not about a margin transformation that has yet to begin.

The methods split cleanly along a single line, and the line is growth. Approaches that credit forward growth, the cash-flow models and the peer-multiple comparisons, land above today's price. Approaches that do not, the asset-value and earnings-power families, land well below it: the price sits about 57 percent above the asset-value methods and about 85 percent above the earnings-power methods, the latter simply capitalizing current profit at a required return with nothing assumed about the future. Nothing in the balance sheet or in current earnings alone defends this quote. The growth does, or it does not.

How the growth methods reach their answer is worth stating plainly, because the assumption is doing visible work. The exit-multiple cash-flow model holds today's 13.5x EV/EBITDA flat as the exit assumption, with 11.5x in the bear scenario and 15.5x in the bull. The forward market-value approach works from revenue of $20.6 billion compounding at 18 percent with terminal price-to-sales held flat at today's 3.5x. Both land above the current quote, and both do so on the arithmetic that today's rating persists. Neither is unreasonable. Both are assumptions rather than findings.

Against the cohort, this is a middle-of-the-pack bet rather than a stretched one. Trailing operating margins run 17.8 percent at MDT, 21.4 percent at SYK and 17.1 percent at ABT, with Boston Scientific's roughly 18.4 percent sitting inside that range, and its recent quarterly growth of 7.5 percent reported is comparable to the 8.4 percent and 8.5 percent trailing-year rates at MDT and SYK. Where it stands apart is at the specialist end of the group: ISRG grows 20.7 percent at a 31.3 percent operating margin, which is what a genuinely differentiated platform looks like and what this valuation does not require.

The balance sheet neither supports nor threatens the case, and the useful way to see it is through coverage rather than through totals. Operating income covers the interest bill roughly 10.6 times over, with $96 million of interest expense in the June quarter against $1,178 million of operating income. What changed this year is liquidity rather than solvency. The balance held in cash and equivalents dropped to 539 million dollars on June 30, 2026 from 1,965 million at the year end, spent on the completed repurchase and the MiRus stake, while other investments rose to $2,245 million from $681 million as a result. The company converted spare liquidity into retired shares and into an option on a valve platform. That is a deliberate trade, and it is the clearest statement in the accounts about where management thinks the next several years of value are made.

Catalysts

The guidance revision issued on July 29, 2026 is the item that most directly reprices the story. Full-year 2026 net sales growth is now estimated at approximately 5.5 to 6.5 percent reported and 5 to 6 percent organic, with adjusted earnings, which exclude certain charges and credits, guided to $3.28 to $3.32 a share. Third-quarter growth is guided to approximately 3 to 5 percent on both a reported and organic basis. That third-quarter figure is the number to watch, because the gap between it and the 7.0 percent organic rate just delivered is the single largest open question in the near-term story.

The restructuring programme runs alongside it on a longer clock. Approved by the board on July 21, 2026, the plan covers supply chain optimization including the transfer of production lines between facilities, functional transformation and organizational changes, with headcount reductions expected. Total pre-tax charges are estimated at $700 million to $800 million, of which $600 million to $700 million is expected to become cash outlays, against roughly $500 million of gross annual pre-tax expense reduction as the benefits arrive; the programme is expected to be substantially complete by the end of 2029. Charges of that size land in reported results well before the savings do, so the next several quarters will look worse on a GAAP basis than the underlying business is performing.

On the clinical side the calendar is unusually full. The AVANT GUARD study of FARAPULSE pulsed field ablation met all safety and effectiveness endpoints in persistent atrial fibrillation and showed statistical superiority over anti-arrhythmic drugs in previously untreated patients, the ELEVATE-PF feasibility study of the FARAFLEX mapping and ablation catheter reported durable lesions with no pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke, and enrolment has begun in the pivotal FARADIGM trial of that same catheter. The company also received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter, and presented FRACTURE trial results for an investigational coronary intravascular lithotripsy catheter that met its primary endpoints. Pivotal-trial readouts and clearances are the mechanism by which this company converts research spending into new procedure volume, and several of them now have dates attached.

Peer Cohorts (Per Segment, With Filing Citations)

MedSurg (reported)

• EW (EDWARDS LIFESCIENCES CORPORATION)
• FY2025 10-K: …product innovation, robust and expanding clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes. Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively. Surgical Structural Heart We…
• FY2025 10-K: …considerations, regulatory reform, industry and customer consolidation, and evolving patient needs. The ability to provide products and technologies that demonstrate value while improving clinical outcomes is becoming increasingly important for medical technology manufacturers. We believe that we are a leading global…
• MDT (Medtronic plc)
• FY2025 10-K: …move with speed and decisiveness, foster belonging, and deliver results… the right way. Our culture helps us meet the needs of our patients and customers, and ensures our Mission endures for many years to come. Health & Safety As a large, global employer, our ability to attract and retain talent is based in part on…
• FY2025 10-K: 2019, by and among Medtronic plc, Medtronic Global Holdings S.C.A., Medtronic, Inc., Wells Fargo Bank, N.A., and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc's Current Report on Form 8-K, filed on March 7, 2019, File No. 001-36820). 4.25 Third Supplemental…
• SYK (STRYKER CORP)
• FY2025 10-K: …better. We offer innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our goal is to achieve sales growth at the high-end of the medical technology…
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• ISRG (Intuitive Surgical, Inc.)
• FY2025 10-K: …also be impacted by the competition we currently face, or expect to face, from companies offering products for open or MIS surgeries, companies providing other therapeutic approaches for target clinical conditions, and companies developing diagnostic solutions that could serve as alternatives to current or planned…
• FY2025 10-K: MIS products. We believe that the entrance or emergence of competition validates MIS and robotic-assisted surgery or robotic-assisted bronchoscopy. Moreover, as we add new robotically controlled products (e.g., da Vinci stapling and da Vinci energy products) that compete with product offerings traditionally within the…
• DXCM (DEXCOM, INC.)
• FY2025 10-K: …new product introductions and other market activities of industry participants. In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc's Diabetes Group (which implemented a spinoff of its diabetes business into a separate company called MiniMed);…
• FY2025 10-K: …diabetes research are continually seeking ways to prevent, cure or improve treatment of diabetes. Therefore, our products may be rendered obsolete by technological breakthroughs in diabetes monitoring, treatment, prevention or cure. In selling our G6, G7, G7 15 Day, Dexcom One and Dexcom ONE+, we compete directly…
• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc. There are smaller competitors in these product categories as well that focus on smaller subsegments of the…
• FY2025 10-K: …premarket and post-market requirements. Products currently certified per the MDD regulations must be certified to the new EU MDR regulation prior to December 2027 or December 2028, depending upon the device's risk class. The UK additionally is in the process of creating secondary legislation to implement the future…
• SOLV (SOLVENTUM CORPORATION)
• FY2025 10-K: …and manufacturing expertise. We serve a diverse customer base, ranging from multidisciplinary hospitals to local clinics/practices. Our long-tenured and collaborative customer relationships globally give us unique insights into their needs and preferences. These insights inform our innovation processes, drive…
• FY2025 10-K: …to the same period last year. The decrease was primarily driven by the impact of higher product costs due to tariffs, logistics and a full year of supply agreement mark-ups from 3M. Year 2024 results: Sales in MedSurg were up 0.1%: • Organic sales growth of 1.2% was driven by volumes, primarily due to benefits from…
• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …country:US bdx:PharmaceuticalSystemsMember bdx:MedicalMember 2024-10-01 2025-09-30 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:PharmaceuticalSystemsMember bdx:MedicalMember 2024-10-01 2025-09-30 0000010795 us-gaap:OperatingSegmentsMember bdx:PharmaceuticalSystemsMember bdx:MedicalMember…
• FY2025 10-K: …us-gaap:NonUsMember bdx:UrologyandCriticalCareMember bdx:InterventionalMember 2023-10-01 2024-09-30 0000010795 us-gaap:OperatingSegmentsMember bdx:UrologyandCriticalCareMember bdx:InterventionalMember 2023-10-01 2024-09-30 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:UrologyandCriticalCareMember…

Cardiovascular (reported)

• MDT (Medtronic plc)
• FY2025 10-K: …stapling and energy platform. • Our ability to execute ongoing strategies addressing the pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S. • Our ability to create markets and drive products and procedures into emerging…
• FY2025 10-K: …a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. The division also provides biologic solutions for the orthopedic markets and offers unique and highly differentiated imaging, navigation, power instruments, and robotic guidance systems used in spine…
• SYK (STRYKER CORP)
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• FY2025 10-K: …better. We offer innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our goal is to achieve sales growth at the high-end of the medical technology…
• ABT (ABBOTT LABORATORIES)
• FY2025 10-K: …across all businesses, with double-digit growth in Diabetes Care, Heart Failure, Electrophysiology, and Structural Heart, and in 2025, Rhythm Management. Growth was led by Diabetes Care where sales of Abbott's continuous glucose monitoring (CGM) systems continued to increase and totaled $7.6 billion in 2025 and $6.4…
• FY2025 10-K: …including consumers, pharmacists, physicians, and other healthcare providers. Government agencies are also important customers. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term "Abbott" refers to Abbott Laboratories, an Illinois corporation,…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.